The interferon-?1b clinical trial and its implications for other trials
- 1 January 1994
- journal article
- clinical trial
- Published by Wiley in Annals of Neurology
- Vol. 36 (S1) , S113-S114
- https://doi.org/10.1002/ana.410360726
Abstract
This trial was monitored by both clinical and magnetic resonance imaging (MRI) methods. Clinical effect was a 30% reduction in relapse rate in the group treated with a high dose. The MRI activity rate was reduced by a median of 70% in both treatment groups. The burden of disease measure showed a clear-cut dose effect in the 2-year analysis. Future trials must be monitored by MRI. In addition, placebo controls will continue to be necessary in most trials, especially if long-term effects are to be measured.Keywords
This publication has 7 references indexed in Scilit:
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- The pathological evolution of multiple sclerosisNeuropathology and Applied Neurobiology, 1992
- Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.American Journal of Roentgenology, 1991
- Internuclear ophthalmoplegia in the Chiari type II malformationNeurology, 1990
- Proton magnetic resonance spectroscopy in multiple sclerosisNeurology, 1990
- CORRELATION BETWEEN NMR SCAN AND BRAIN SLICE DATA IN MULTIPLE SCLEROSISThe Lancet, 1984